First Time Loading...

MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 6.29 USD 2.11% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. [ Read More ]

The intrinsic value of one MDXG stock under the Base Case scenario is 6.24 USD. Compared to the current market price of 6.29 USD, MiMedx Group Inc is Overvalued by 1%.

Key Points:
MDXG Intrinsic Value
Base Case
6.24 USD
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
MiMedx Group Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MDXG stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
MiMedx Group Inc

Provide an overview of the primary business activities
of MiMedx Group Inc.

What unique competitive advantages
does MiMedx Group Inc hold over its rivals?

What risks and challenges
does MiMedx Group Inc face in the near future?

Has there been any significant insider trading activity
in MiMedx Group Inc recently?

Summarize the latest earnings call
of MiMedx Group Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MiMedx Group Inc.

Provide P/S
for MiMedx Group Inc.

Provide P/E
for MiMedx Group Inc.

Provide P/OCF
for MiMedx Group Inc.

Provide P/FCFE
for MiMedx Group Inc.

Provide P/B
for MiMedx Group Inc.

Provide EV/S
for MiMedx Group Inc.

Provide EV/GP
for MiMedx Group Inc.

Provide EV/EBITDA
for MiMedx Group Inc.

Provide EV/EBIT
for MiMedx Group Inc.

Provide EV/OCF
for MiMedx Group Inc.

Provide EV/FCFF
for MiMedx Group Inc.

Provide EV/IC
for MiMedx Group Inc.

Show me price targets
for MiMedx Group Inc made by professional analysts.

What are the Revenue projections
for MiMedx Group Inc?

How accurate were the past Revenue estimates
for MiMedx Group Inc?

What are the Net Income projections
for MiMedx Group Inc?

How accurate were the past Net Income estimates
for MiMedx Group Inc?

What are the EPS projections
for MiMedx Group Inc?

How accurate were the past EPS estimates
for MiMedx Group Inc?

What are the EBIT projections
for MiMedx Group Inc?

How accurate were the past EBIT estimates
for MiMedx Group Inc?

Compare the revenue forecasts
for MiMedx Group Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MiMedx Group Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MiMedx Group Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of MiMedx Group Inc compared to its peers.

Compare the P/E ratios
of MiMedx Group Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing MiMedx Group Inc with its peers.

Analyze the financial leverage
of MiMedx Group Inc compared to its main competitors.

Show all profitability ratios
for MiMedx Group Inc.

Provide ROE
for MiMedx Group Inc.

Provide ROA
for MiMedx Group Inc.

Provide ROIC
for MiMedx Group Inc.

Provide ROCE
for MiMedx Group Inc.

Provide Gross Margin
for MiMedx Group Inc.

Provide Operating Margin
for MiMedx Group Inc.

Provide Net Margin
for MiMedx Group Inc.

Provide FCF Margin
for MiMedx Group Inc.

Show all solvency ratios
for MiMedx Group Inc.

Provide D/E Ratio
for MiMedx Group Inc.

Provide D/A Ratio
for MiMedx Group Inc.

Provide Interest Coverage Ratio
for MiMedx Group Inc.

Provide Altman Z-Score Ratio
for MiMedx Group Inc.

Provide Quick Ratio
for MiMedx Group Inc.

Provide Current Ratio
for MiMedx Group Inc.

Provide Cash Ratio
for MiMedx Group Inc.

What is the historical Revenue growth
over the last 5 years for MiMedx Group Inc?

What is the historical Net Income growth
over the last 5 years for MiMedx Group Inc?

What is the current Free Cash Flow
of MiMedx Group Inc?

Financials

Balance Sheet Decomposition
MiMedx Group Inc

Current Assets 164.3m
Cash & Short-Term Investments 82m
Receivables 53.9m
Other Current Assets 28.4m
Non-Current Assets 74.8m
PP&E 9.1m
Intangibles 24.7m
Other Non-Current Assets 41m
Current Liabilities 46m
Accounts Payable 9m
Accrued Liabilities 33.2m
Other Current Liabilities 3.8m
Non-Current Liabilities 50.3m
Long-Term Debt 48.1m
Other Non-Current Liabilities 2.2m
Efficiency

Earnings Waterfall
MiMedx Group Inc

Revenue
321.5m USD
Cost of Revenue
-54.6m USD
Gross Profit
266.8m USD
Operating Expenses
-224.6m USD
Operating Income
42.3m USD
Other Expenses
13.5m USD
Net Income
55.8m USD

Free Cash Flow Analysis
MiMedx Group Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MDXG Profitability Score
Profitability Due Diligence

MiMedx Group Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

51/100
Profitability
Score

MiMedx Group Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

MDXG Solvency Score
Solvency Due Diligence

MiMedx Group Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
72/100
Solvency
Score

MiMedx Group Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MDXG Price Targets Summary
MiMedx Group Inc

Wall Street analysts forecast MDXG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDXG is 12.75 USD with a low forecast of 11.11 USD and a high forecast of 14.7 USD.

Lowest
Price Target
11.11 USD
77% Upside
Average
Price Target
12.75 USD
103% Upside
Highest
Price Target
14.7 USD
134% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MDXG Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MDXG Price
MiMedx Group Inc

1M 1M
-22%
6M 6M
+3%
1Y 1Y
+79%
3Y 3Y
-42%
5Y 5Y
+124%
10Y 10Y
+8%
Annual Price Range
6.29
52w Low
3.52
52w High
9.14
Price Metrics
Average Annual Return 25.27%
Standard Deviation of Annual Returns 95.56%
Max Drawdown -83%
Shares Statistics
Market Capitalization 919.8m USD
Shares Outstanding 148 076 100
Percentage of Shares Shorted 3.55%

MDXG Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

MiMedx Group Inc Logo
MiMedx Group Inc

Country

United States of America

Industry

Biotechnology

Market Cap

919.8m USD

Dividend Yield

0%

Description

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 811 full-time employees. The company went IPO on 2007-08-20. The firm is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.

Contact

GEORGIA
Marietta
1775 W Oak Commons Ct
+17706519100.0
https://mimedx.com/

IPO

2007-08-20

Employees

811

Officers

General Counsel & Chief Administrative Officer
Mr. William F. Hulse IV
President of Regenerative Medicine & Biologics Innovation
Dr. Robert Benjamin Stein M.D., Ph.D.
CEO & Director
Mr. Joseph H. Capper
Chief Financial Officer
Mr. Douglas C. Rice CPA
Senior Vice President of Operations & Procurement
Mr. Scott M. Turner
Head of Investor Relations
Mr. Matthew M. Notarianni
Show More
Senior VP & Chief Compliance Officer
Mr. Mark P. Graves
Vice President of Investor Relations & Corporate Strategic Communications
Hilary Dixon
Chief Human Resources Officer
Ms. Kate Surdez
Chief Medical Officer
Dr. David H. Mason Jr.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MDXG stock?

The intrinsic value of one MDXG stock under the Base Case scenario is 6.24 USD.

Is MDXG stock undervalued or overvalued?

Compared to the current market price of 6.29 USD, MiMedx Group Inc is Overvalued by 1%.